胃がん治療の日本市場の評価：治療タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測（2019年度～2033年度）

日本の胃がん治療の市場規模は、2025年度の13億5,000万米ドルから2033年度に38億6,000万米ドルに達すると予測され、2026年度～2033年度の予測期間にCAGRで14%の成長が見込まれます。市場の成長は、老年人口の急速な増加や塩分を多く含む食品の消費の増加に起因する胃がん有病率の上昇、革新的な治療法の導入に対する注目の高まり、研究開発活動への投資の増加によるものと考えられます。World Economic Forumの推計によれば、日本では10人に1人以上が80歳以上です。

この疾患の治療法には、化学療法、標的治療、外科的介入に加え、新たな免疫療法の選択肢もあります。早期発見の取り組みと組み合わせられた政府の支援策により、胃がんの早期発見が可能になり、治療成績が向上しています。

さらに、日本におけるピロリ菌感染症の高い有病率も、市場に有利な成長機会をもたらしています。ピロリ菌は胃の病原菌であり、その長続きする病原菌は胃の粘膜を損傷し、がんを引き起こす可能性のある一連の変化を開始させることにつながります。Baishideng Publishing Groupが発表した論文によると、2022年の日本におけるピロリ菌感染症の血清陽性率は全体で37.6%～43.2%でした。国内の強固な医療インフラと民間部門の関与により、先進の治療ソリューションへのアクセスが確保されています。

当レポートでは、日本の胃がん治療市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 日本の胃がん治療市場の見通し（2019年度～2033年度）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 治療タイプ別
    • 免疫療法
    • 標的療法
    • 化学療法
    • その他
  • タイプ別
    • 腺がん
    • 消化管間質腫瘍（GIST）
    • 食道胃接合部がん
  • 薬剤クラス別
    • PD-1/PD-L1阻害薬
    • HER2拮抗薬
    • VEGFR2拮抗薬
    • その他の薬剤クラス
  • 投与経路
    • 経口
    • 注射
  • 流通チャネル別
    • 病院薬局
    • 専門薬局、小売薬局
    • その他
  • 地域別
    • 北部（北海道、東北）
    • 中部（関東、中部）
    • 南部（関西、中国、四国、九州・沖縄）
  • 市場シェア分析：企業別（上位5社とその他 - 金額ベース、2025年度）
• 市場マップ分析（2025年度）
  • 治療タイプ別
  • タイプ別
  • 薬剤クラス別
  • 投与経路
  • 流通チャネル別
  • 地域別

第6章 需給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Novartis Pharma K.K.
  • Pfizer Japan Inc.
  • Viatris Inc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly Japan K.K.
  • Bristol-Myers Squibb K.K.
  • Samsung Bioepis Co., Ltd.
  • Celltrion Healthcare Japan K.K.

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Stomach Cancer Treatment Market, By Value, In USD Billion, FY2019-FY2033F
• Figure 2. Japan Stomach Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 3. Japan Stomach Cancer Treatment Market Share (%), By Type, FY2019-FY2033F
• Figure 4. Japan Stomach Cancer Treatment Market Share (%), By Drug Class, FY2019-FY2033F
• Figure 5. Japan Stomach Cancer Treatment Market Share (%), By Route of Administration, FY2019-FY2033F
• Figure 6. Japan Stomach Cancer Treatment Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 7. Japan Stomach Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 8. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 9. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 10. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 11. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 12. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 13. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2025

Japan stomach cancer treatment market is projected to witness a CAGR of 14% during the forecast period FY2026-FY2033, growing from USD 1.35 billion in FY2025 to USD 3.86 billion in FY2033. The market's growth can be attributed to the rising prevalence of stomach cancer in the country owing to the rapid expansion of the geriatric population and increasing consumption of food products rich in salt, growing focus on introducing innovative therapies, and rising investments in research and development activities. As per the estimates of the World Economic Forum, over 1 in 10 people in Japan are 80 or older.

The treatment landscape for the condition includes chemotherapy, targeted therapy, and surgical intervention along with emerging immunotherapy options. Government-backed initiatives in combination with early detection initiatives are allowing the detection of gastric cancer at earlier stages, improving treatment outcomes.

Moreover, the high prevalence of Helicobacter pylori infection in Japan is also providing lucrative growth opportunities to the market. H. pylori is a gastric pathogen whose chronic pathogen damages the lining of the stomach, resulting in the initiation of a series of changes that can cause cancer. According to an article published by Baishideng Publishing Group, the overall seroprevalence rate of H. pylori infection in Japan was 37.6%-43.2% in 2022. The country's robust healthcare infrastructure and involvement of private sector are ensuring the accessibility to sophisticated treatment solutions.

Increasing Innovations Support Market Expansion

Rising innovations are augmenting the availability of personalized medicines and advanced therapies in Japan. Increasing investments in research and development coupled with the surge in the approval of novel therapies and clinical trials are further bolstering the availability of effective therapeutic solutions. For instance, in April 2025, Hoth Therapeutics, Inc. obtained a new patent from the Japan Patent Office, reinforcing their intellectual property rights in the area of immunological diseases and RNA-based therapies for cancer. This patent strengthens the company's intellectual property position in Japan, enabling exclusive development and commercialization of the innovative RNA therapy. Such advancements expand the therapeutic solutions available to oncologists, allowing them to provide personalized treatment solutions and improving patient outcomes.

Research Efforts Boost Market Growth

Increasing research efforts to bolster the understanding of gastric cancer and the effectiveness of different screening approaches is providing lucrative growth opportunities for the market. Longterm and on-going studies such as the Tokyo Gastric Cancer Screening Study aim to provide valuable data for gastric cancer screening strategies in Japan. The study's collaboration with medical associations and municipal governments in Tokyo is generating valuable data that can be beneficial in the development of future national screening policies. By detecting cancers and precancerous conditions at earlier stages, the program increases the number of patients eligible for curative and minimally invasive treatments, thereby boosting demand for the advanced therapies, and providing lucrative growth opportunities for the market.

High Salt Consumption is Driving the Market's Demand

Traditionally, the Japanese diet has been high in salted, pickled, and smoked foods, as well as preservatives like nitrates, all of which are strongly associated with an increased risk of stomach cancer. Epidemiological studies have consistently shown that high salt intake and the consumption of preserved foods elevate the risk of stomach cancer. The continued consumption of food products rich in salt is driving both the incidence and detection of stomach cancer, leading to an increased demand for advanced diagnostic and therapeutic interventions. Increasing government efforts such as public health campaigns focused on nutritional education, screening, and early detection are also raising awareness and propelling the rate of early diagnosis. Thus, the requirement for effective and innovative treatments is rising, fueling the market's growth in the country.

Targeted Therapies Hold Major Market Share

The different advantages associated with targeted therapies include improved survival rates and higher efficacy due to their ability to specifically attack cancer cells with certain molecular markers and genetic mutations, including HER2, is propelling the segment's growth. Their precise mode of action ensures reduced side effects as compared to chemotherapy, increasing their appeal to both patients and oncologists alike. Thus, various pharmaceutical companies are focusing on developing targeted therapies. For instance, in February 2025, Chugai Pharmaceutical Co., Ltd. received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for its humanized anti-PD-L1 monoclonal antibody/ anti-cancer agent Tecentriq Intravenous Infusion. Such advancements and growing focus on the development of oncological solutions are bolstering the availability of innovative therapies and providing lucrative growth opportunities for the market.

Impact of the U.S. Tariff on Japan Stomach Cancer Treatment Market

The recently introduced tariffs are expected to impact the collaborative efforts and partnerships between the United States and Japanese pharmaceutical companies. Research partnerships and joint ventures among such companies could also face financial damages, potentially slowing the introduction of innovative therapeutic solutions for stomach cancer in Japan.

The tariffs are also expected to propel the treatment expenses for cancer patients and increase the strain on the country's healthcare system, potentially limiting the accessibility of targeted therapies, immunotherapy, and chemotherapy.

Such challenges might encourage domestic pharmaceutical and medical device companies to decrease their reliance on imports and bolster the production of pharmaceutical products and medical devices in Japan.

Key Players Landscape and Outlook

Rising product approvals from the MHLW for new therapies are allowing clinicians to gain access to therapeutic solutions that are tailored to diverse genetic profiles, improving treatment outcomes. For instance, in March 2024, Astellas Pharma Inc. received approval from the MHLW for VYLOY (zolbetuximab), for patients with advanced or recurrent, unresectable, and CLDN18.2 positive, gastric cancer. The approval is based on clinical trials that demonstrated improvements in the overall survival and progression of the disease when VYLOY was administered in combination with chemotherapy. Such approvals ensure that the patient population is equipped with viable treatment options and also stimulate competition among regional pharmaceutical companies to accelerate the introduction of innovative therapies, positively influencing the market's expansion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Japan Stomach Cancer Treatment Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Immunotherapy
    • 5.2.1.2. Targeted Therapy
      • 5.2.1.2.1. Biologics
      • 5.2.1.2.2. Biosimilar
    • 5.2.1.3. Chemotherapy
      • 5.2.1.3.1. Capecitabine
      • 5.2.1.3.2. Cisplatin
      • 5.2.1.3.3. Fluorouracil (5-FU)
      • 5.2.1.3.4. Oxaliplatin
      • 5.2.1.3.5. Others
    • 5.2.1.4. Others
  • 5.2.2. By Type
    • 5.2.2.1. Adenocarcinomas
    • 5.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
    • 5.2.2.3. Gastroesophageal Junction Cancer
  • 5.2.3. By Drug Class
    • 5.2.3.1. PD-1/PD-L1 Inhibitors
    • 5.2.3.2. HER2 Antagonists
    • 5.2.3.3. VEGFR2 Antagonists
    • 5.2.3.4. Other Drug Classes
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Injectable
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Specialty and Retail Pharmacies
    • 5.2.5.3. Others
  • 5.2.6. By Region
    • 5.2.6.1. North [Hokkaido and Tohoku]
    • 5.2.6.2. Central [Kanto and Chubu]
    • 5.2.6.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Treatment Type
  • 5.3.2. By Type
  • 5.3.3. By Drug Class
  • 5.3.4. By Route of Administration
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Pharma K.K.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Pfizer Japan Inc.
  • 16.3.3. Viatris Inc.
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. F. Hoffmann-La Roche Ltd
  • 16.3.6. Teva Pharmaceutical Industries Ltd.
  • 16.3.7. Eli Lilly Japan K.K.
  • 16.3.8. Bristol-Myers Squibb K.K.
  • 16.3.9. Samsung Bioepis Co., Ltd.
  • 16.3.10. Celltrion Healthcare Japan K.K.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer